Dont Get Blind-Sided: The Critical Drug Patent Mistakes to Avoid in MA Due Diligence
In Massachusetts, due diligence cant be a checkbox exerciseespecially when the asset youre evaluating is a drug product with a patent landscape thats anything but stat…

Post-Approval Patents: The Hidden Loe Risk Map Pharma Cant Afford to Ignore
Most teams think the patent story ends at approval.
They shouldnt.
In the post-approval world, the real risk often hides in plain sight: patents that are filed, asserted, or st…

Post-Approval Patents: The Hidden Loe Risk Map Pharma Cant Afford to Ignore
Most teams think the patent story ends at approval.
They shouldnt.
In the post-approval world, the real risk often hides in plain sight: patents that are filed, asserted, or st…

The 20-Year Myth Is Costing PharmaHeres What Actually Determines Drug Exclusivity
If youve ever heard that a drugs market exclusivity is simply 20 years, youve heard a comforting simplificationone that can lead to expensive misreads of timing, strategy…

Pharma mega-deals dont happen because of hype. They happen because of exclusivity.
Behind every headlinewhether its a blockbuster acquisition, a licensing windfall, or a portfolio swapis a quiet, high-stakes question: How long can the buyer keep compet…

Drug Patent Cliff Forecasting: How to Predict Price Erosion Before It Happens
The market doesnt wait for you to notice the cliff.
One day, a blockbuster is protected by patents and exclusivity. The next, generic and biosimilar entrants arriveoften fast…

Post-approval is where many drug strategies quietly fail.
The science may be done. The trial results may be in. But the real riskregulatory and IPoften accelerates after approval, not before. If youre a pharma leader, counsel, or BD executive, the ques…

Post-approval is where the real IP game starts.
Most teams obsess over getting to approval—then quietly assume the hard part is over. It isn’t. In the months and years after launch, your product becomes a target: for generic challengers, for “evergre…

Pharma companies dont lose exclusivity because they missed a deadline. They lose it because they misread the battlefield.
In patent strategy, the real risk isnt just litigationits litigation plus the erosion of market position that comes when challenge…

Humira to Keytruda: The Blueprint for Surviving the Composition-of-Matter Cliff
The composition-of-matter cliff isnt a metaphor. Its a calendar.
One day, a blockbusters patent moat is intact. The next, the market starts pricing in generic and biosimila…